Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 0.79 |
| ▸ | KDR | P35968 | 10/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.79 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.79 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.79 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.79 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.79 |
| ▸ | TLK1 | Q9UKI8 | 3/20 | 0.79 |
| ▸ | PLK4 | O00444 | 3/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.79 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.79 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.79 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.79 |
| ▸ | INSR | P06213 | 3/20 | 0.79 |
| ▸ | LCK | P06239 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484145 | 1.00 | PDGFRB (0.79) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4493905 | 1.00 | PDGFRB (0.79) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4484149 | 1.00 | PDGFRB (0.79) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4492992 | 0.91 | KDR (0.65) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4492990 | 0.91 | KDR (0.65) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4487550 | 0.91 | KDR (0.65) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4487543 | 0.91 | KDR (0.65) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4485972 | 0.89 | KDR (0.63) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4482620 | 0.89 | KDR (0.63) | PDGFRBKDRFGFR1PRKAA1PRKAA2 | |
| SCHEMBL4482616 | 0.89 | KDR (0.63) | PDGFRBKDRFGFR1PRKAA1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | claimed |
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1370554-B1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | PDGFRB 687/4885KDR 762/4885FGFR1 848/4885 |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | MAP3K15, MAP3K19, MAP3K9 | PDGFRB 1174/4885KDR 1384/4885FGFR1 1045/4885 |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | PDPK1, MKNK1, PKN2 | PDGFRB 948/4885KDR 1298/4885FGFR1 1284/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | PDGFRB 1062/4885KDR 1334/4885FGFR1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.